Search | Clinical Trials Finder

Conditions: Corona Virus Infection, ARDS, ARDS, Human, Acute Respiratory Distress Syndrome, COVID-19
Interventions: Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care., Vehicle + Heparin along with best supportive care; Biological · Other
Lead sponsor: Camillo Ricordi; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Appendectomy, Appendicitis, Appendicitis Acute
Interventions: Infection-Prediction Algorithm; Device
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 18 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • Maywood, Illinois • Winfield, Illinois

Conditions: COVID-19, SARS-CoV-2
Interventions: Abatacept, Placebo; Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Hialeah, Florida • Louisville, Kentucky • Boston, Massachusetts + 2 more

Conditions: Acute Otitis Media
Interventions: Amoxicillin-Clavulanate, 10 days, Amoxicillin-Clavulanate, 5 days; Drug
Lead sponsor: Alejandro Hoberman; Other
Eligibility: 6 Months to 23 Months
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Bardstown, Kentucky • Pittsburgh, Pennsylvania

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions: rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, methotrexate; Biological · Drug · Procedure
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes, Quality of Life
Interventions: cognitive assessment, management of therapy complications, psychosocial assessment and care, quality-of-life assessment; Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Interventions: REGENECYTE®; Biological
Lead sponsor: StemCyte, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Miami, Florida • Miami Lakes, Florida

Conditions: Long COVID, PASC Post Acute Sequelae of COVID 19
Interventions: Valacyclovir celecoxib dose 1, Valacyclovir celecoxib dose 2, Placebo; Drug
Lead sponsor: Bateman Horne Center; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Influenza, Novel Respiratory Virus-1 Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), Novel Respiratory Virus-2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)
Interventions: Not listed
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2024
U.S. locations: 18
States / cities: San Diego, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more

Conditions: Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic Leukemia
Interventions: CPX-351; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Acute Bacterial Skin and Skin Structure Infection
Interventions: Oritavancin, Warfarin; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Somers Point, New Jersey

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Neutropenia, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: cefepime hydrochloride, levofloxacin; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SARS
Interventions: Aluminum hydroxide adjuvant (Alhydrogel®), Phosphate buffered saline Placebo, Recombinant S protein SARS vaccine; Drug · Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 3
States / cities: Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio

Conditions: Covid19, SARS-CoV Infection
Interventions: Sargramostim, Placebo; Drug
Lead sponsor: Partner Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 34
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more

Conditions: HIV Infections
Interventions: HST-NEETs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia

Conditions: COVID Long-Haul
Interventions: [11C]CPPC Injection; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder
Interventions: beta-glucan, rituximab; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Perforated Appendicitis
Interventions: Appendectomy, Observation; Procedure · Other
Lead sponsor: Marshall University; Other
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Huntington, West Virginia

Conditions: ARDS, Covid19, Acute Hypoxemic Respiratory Failure
Interventions: Prolonged Proned Positioning, Traditional Proning Arm; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 99 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Childhood Langerhans Cell Histiocytosis, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: umbilical cord blood transplantation; Procedure
Lead sponsor: Herbert Irving Comprehensive Cancer Center; Other
Eligibility: Up to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: New York, New York

Conditions: B-Cell Acute Lymphoblastic Leukaemia, ALL, Adult, B-ALL
Interventions: Blinatumomab, Haplo-Mismatched Cell Therapy (HMCT); Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
Interventions: Losartan, Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 13
States / cities: Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more

Search by objective public record fields.

Use of UC-MSCs for COVID-19 Patients

Early Detection of Infection Using the Fitbit in Pediatric Surgical Patients

Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise

Efficacy of Short-Course Antimicrobial Treatment for Children With Acute Otitis Media and Impact on Resistance

Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen

Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2

Saliva as Source of Detection for SARS-CoV-2

Respiratory Virus Hospitalization Study (FLU 003 Plus)

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

A Study to Evaluate the Safety of a Single Intravenous (IV) Dose of Orbactiv (Oritavancin) in Participants on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia

Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study

Sargramostim Use in COVID-19 to Recover Patient Health

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Long COVID-19 [11C]CPPC Study

Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation

The Management of Perforated Acute Appendicitis in Adult and Pediatric Populations

Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS)

Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia

Blinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALL

Losartan for Patients With COVID-19 Requiring Hospitalization